LY2334737

TargetMol
Product Code: TAR-T4061
Supplier: TargetMol
CodeSizePrice
TAR-T4061-1mg1mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4061-2mg2mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4061-1mL1 mL * 10 mM (in DMSO)£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4061-5mg5mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4061-10mg10mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4061-25mg25mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4061-50mg50mg£646.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4061-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity.
CAS:
892128-60-8
Formula:
C17H25F2N3O5
Molecular Weight:
389.4
Pathway:
; Microbiology/Virology; DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
1
SMILES:
CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Target:
Nucleoside Antimetabolite/Analog; Virus Protease

References

Cai Y, Zhou H, Zhu Y, et al. Elimination of senescent cells by ?-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Research. 2020: 1-16. Francia G, et al. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar;11(3):680-9. Pratt SE, et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19(5):1159-68. Koolen SL, et al. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2011 Sep 15;17(18):6071-82. Cai Y, Zhou H, Zhu Y, et al. Elimination of senescent cells by ?-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice[J]. Cell Research. 2020: 1-16.